Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JMA Chides MHLW for Information Provisioning on Cefazolin Shortage
The Japan Medical Association (JMA) is urging the Ministry of Health, Labor and Welfare (MHLW) to do a better job at providing information on the antibiotic cefazolin, which has been in short supply, to frontline healthcare providers by determining their…
To read the full story
Related Article
- GSK Japan to Pull Prescribed Zantac and Compensate for Substitutes; Generic Peers Follow
October 11, 2019
- All 11 Manufacturers Pull Ranitidine from Shelves, “Class I” Recalls for 9 Firms
October 4, 2019
- Nichi-Iko Aims to Resume Stable Supply of Cefazolin by Year-End: Exec
May 14, 2019
- With Continuing Shortage of Cefazolin, Shipments of 21 Substitutes Being Adjusted Too
April 8, 2019
- Cefazolin Generic Shortage Raises Worries of Supply Crunch after G1 LLP Withdrawals
April 4, 2019
ORGANIZATION
- LINK-J Eyes Stronger Ties with AI, Semiconductor Sectors
September 2, 2026
- JGA Unveils Industry Vision 2035, Eyes Sustainable Structure
September 2, 2026
- Ex-JMA Vice President Takashi Hanyuda Dies at 78
August 27, 2026
- Pharma Labor Group Logs Wage Hikes of around 4% at July-End
August 24, 2026
- Biotech Group Calls for Post-IPO Startups to Get AMED Support
August 19, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…